TransMedics, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation. Its Organ Care System preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. Its Organ Care System incudes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains organs in a near physiologic state and enables surgeons to perfuse and ventilate the organ between the donor and recipient sites; OCS Heart, a portable heart perfusion system that helps to maintain organs in a warm functioning state outside of the body; and OCS Liver, a portable perfusion and monitoring system that maintains organs in a near physiologic state. The company offers its products in the United States and internationally. TransMedics, Inc. is headquartered in Andover, Massachusetts. TransMedics, Inc. is a subsidiary of Transmedics Group, Inc.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
CIKN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date2/19/2020 (Estimated)
OptionableNot Optionable
TransMedics Group (NASDAQ:TMDX) Frequently Asked Questions
What is TransMedics Group's stock symbol?
TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."
How were TransMedics Group's earnings last quarter?
TransMedics Group Inc (NASDAQ:TMDX) issued its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.39) EPS for the quarter, topping analysts' consensus estimates of ($0.47) by $0.08. The firm earned $7.21 million during the quarter, compared to analyst estimates of $6.67 million. View TransMedics Group's Earnings History.
When is TransMedics Group's next earnings date?
What price target have analysts set for TMDX?
4 Wall Street analysts have issued twelve-month target prices for TransMedics Group's shares. Their forecasts range from $28.00 to $37.00. On average, they expect TransMedics Group's share price to reach $33.00 in the next twelve months. This suggests a possible upside of 72.0% from the stock's current price. View Analyst Price Targets for TransMedics Group.
What is the consensus analysts' recommendation for TransMedics Group?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TransMedics Group.
Has TransMedics Group been receiving favorable news coverage?
Media headlines about TMDX stock have been trending neutral this week, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. TransMedics Group earned a coverage optimism score of 0.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for TransMedics Group.
Are investors shorting TransMedics Group?
TransMedics Group saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,580,000 shares, an increase of 6.0% from the January 15th total of 1,490,000 shares. Based on an average daily volume of 204,600 shares, the short-interest ratio is presently 7.7 days. Approximately 12.8% of the company's shares are sold short. View TransMedics Group's Current Options Chain.
What other stocks do shareholders of TransMedics Group own?
Who are TransMedics Group's key executives?
TransMedics Group's management team includes the folowing people:
- Dr. Waleed H. Hassanein, Pres, CEO & Director (Age 51)
- Mr. Stephen Gordon, CFO, Treasurer & Sec. (Age 51)
- Mr. John F. Carey, VP of Operations (Age 55)
- Mr. Ike Okonkwo, VP of Fin. & Accounting (Age 48)
- Mr. Brian Thomson, VP of HR (Age 51)
When did TransMedics Group IPO?
(TMDX) raised $75 million in an initial public offering (IPO) on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.
Who are TransMedics Group's major shareholders?
TransMedics Group's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Credit Suisse AG (5.35%), Sandhill Capital Partners LLC (3.48%), Emerald Advisers LLC (2.13%), Emerald Mutual Fund Advisers Trust (2.03%) and Roubaix Capital LLC (1.25%). Company insiders that own TransMedics Group stock include David Weill, Edwin M Kania Jr and Tamer I Khayal. View Institutional Ownership Trends for TransMedics Group.
Which institutional investors are buying TransMedics Group stock?
TMDX stock was acquired by a variety of institutional investors in the last quarter, including Credit Suisse AG, Emerald Advisers LLC, Sandhill Capital Partners LLC, Emerald Mutual Fund Advisers Trust, State Street Corp, Roubaix Capital LLC, Oregon Public Employees Retirement Fund and Harbour Capital Advisors LLC. Company insiders that have bought TransMedics Group stock in the last two years include David Weill and Edwin M Kania Jr. View Insider Buying and Selling for TransMedics Group.
How do I buy shares of TransMedics Group?
Shares of TMDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is TransMedics Group's stock price today?
One share of TMDX stock can currently be purchased for approximately $19.19.
MarketBeat Community Rating for TransMedics Group (NASDAQ TMDX)
MarketBeat's community ratings are surveys of what our community members think about TransMedics Group and other stocks. Vote "Outperform" if you believe TMDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TMDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
